Oncolytics Biotech Files 6-K Report
Ticker: ONCY · Form: 6-K · Filed: Jun 24, 2024 · CIK: 1129928
| Field | Detail |
|---|---|
| Company | Oncolytics Biotech INC (ONCY) |
| Form Type | 6-K |
| Filed Date | Jun 24, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, corporate-update, foreign-private-issuer
Related Tickers: ONCY
TL;DR
ONCOLYTICS BIOTECH (ONCY) filed a 6-K, confirming its foreign private issuer status and Canadian base.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on June 24, 2024, reporting as a foreign private issuer. The filing indicates the company is submitting its report under the 1934 Securities Exchange Act and will file annual reports under Form 20-F. The company's principal executive offices are located in Calgary, Alberta, Canada.
Why It Matters
This filing provides routine corporate updates for investors and regulatory bodies, confirming the company's reporting status and location.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new material financial or operational information.
Key Players & Entities
- ONCOLYTICS BIOTECH INC (company) — Filer of the report
- June 24, 2024 (date) — Date of the filing
- Calgary, Alberta, Canada (location) — Location of principal executive offices
- Form 6-K (document) — Type of SEC filing
- Form 20-F (document) — Annual report form
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information as a foreign private issuer to the U.S. Securities and Exchange Commission, as required by the Securities Exchange Act of 1934.
Where are Oncolytics Biotech Inc.'s principal executive offices located?
Oncolytics Biotech Inc.'s principal executive offices are located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
Which form does Oncolytics Biotech Inc. indicate it will file for its annual reports?
Oncolytics Biotech Inc. indicates it will file its annual reports under cover of Form 20-F.
What is the filing date of this Form 6-K?
This Form 6-K was filed on June 24, 2024.
Is Oncolytics Biotech Inc. submitting this Form 6-K in paper format?
The filing indicates that the registrant is not submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1), as that rule only permits paper submission solely to provide an attached annual report to security holders.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17 · Accepted 2024-06-24 15:52:35
Filing Documents
- form6kmedicalleaveofabsence.htm (6-K) — 18KB
- medicalleaveofabsencepr.htm (EX-99.1) — 14KB
- 0001129928-24-000048.txt ( ) — 33KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date June 24, 2024 Kirk Look Chief Financial Officer